Our genitourinary (GU) oncology faculty are on the cutting edge of GU cancer research and treatment. Our work is supported by the National Cancer Institute, Department of Defense and other industry collaborations.

Through Phase I, II and III clinical trials—in addition to FDA-approved systemic treatments and interventions—we bring the most cutting-edge and promising treatments to our patients.